Article
Biochemistry & Molecular Biology
Changwon Yang, Jisoo Song, Sunwoo Park, Jiyeon Ham, Wonhyoung Park, Hahyun Park, Garam An, Taeyeon Hong, Hee Seung Kim, Gwonhwa Song, Whasun Lim
Summary: This study investigated the effects of quercetin on colorectal cancer cells and found that quercetin can suppress thymidylate synthase levels and induce oxidative stress and calcium dysregulation. It also regulates the expression of specific tiRNAs and enhances apoptosis in CRC cells. Quercetin treatment in colitis-associated CRC mice showed enhanced sensitivity to 5-FU and reduced tumor growth. These findings suggest that quercetin has the potential to be used as an adjuvant with 5-FU for the treatment of CRC.
Article
Cell Biology
Dong Woo Kang, Won Chan Hwang, Yu Na Noh, Youra Kang, Younghoon Jang, Jung-Ae Kim, Do Sik Min
Summary: Phospholipase D1 (PLD1) is identified as a transcriptional target of histone deacetylase (HDAC) inhibitors and contributes to drug resistance in GBM. Inhibiting PLD1 can enhance the efficacy of HDAC inhibitors in treating GBM.
JOURNAL OF CELLULAR PHYSIOLOGY
(2021)
Article
Nanoscience & Nanotechnology
Yi-Qing Chen, Wen-Ting Zhu, Cai-Yan Lin, Zhong-Wen Yuan, Zhen-Hua Li, Peng-Ke Yan
Summary: This study successfully constructed a liposome delivery system for rapamycin to enhance its efficacy in treating colorectal cancer. The rapamycin liposomes showed superior antitumor effects compared to free rapamycin both in vitro and in vivo, and were able to synergistically enhance the efficacy of 5-FU in colorectal cancer via the Akt/mTOR and P53 pathways.
INTERNATIONAL JOURNAL OF NANOMEDICINE
(2021)
Article
Biochemistry & Molecular Biology
Changwon Yang, Jisoo Song, Sunjae Hwang, Jungil Choi, Gwonhwa Song, Whasun Lim
Summary: The study found that apigenin enhances the inhibitory effect of 5-FU on colorectal cancer cells by suppressing TS expression, promoting apoptosis, and disrupting the cell cycle. Additionally, apigenin increases reactive oxygen species production and intracellular calcium levels, indicating its potential to improve therapeutic efficacy.
Article
Biochemistry & Molecular Biology
Chinatsu Kurasaka, Yoko Ogino, Akira Sato
Summary: This study identified that 5-FU-resistant cells exhibit increased TS expression and utilize the TS enzyme to trap the active metabolite FdUMP, resulting in resistance to 5-FU and its analogs.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Article
Oncology
Ai-Wei Feng, Jian-Hai Guo, Song Gao, Fu-Xin Kou, Shao-Xing Liu, Peng Liu, Hui Chen, Xiao-Dong Wang, Hai-Feng Xu, Guang Cao, Xu Zhu
Summary: This study compared the efficacy and safety of HAI with TOMOX and FOLFOX for unresectable CRCLM. The results showed comparable primary outcome measures between the two treatment regimens, but TOMOX had a shorter HAI time.
FRONTIERS IN ONCOLOGY
(2022)
Article
Biochemistry & Molecular Biology
Yong-Hwi Kang, Jin-Seok Lee, Nam-Hun Lee, Seung-Hyung Kim, Chang-Seob Seo, Chang-Gue Son
Summary: Colorectal cancer (CRC) is the third most common cancer worldwide among both men and women, with early detection and resection being the best treatment and chemotherapy a main treatment option. Coptidis Rhizoma extract (CRE) shows potential as an adjuvant agent against 5-FU-resistant colorectal cancers by reducing cell viability and inhibiting thymidylate synthase (TS) expression.
Article
Oncology
Atul Batra, Rodrigo Rigo, Malek B. Hannouf, Winson Y. Cheung
Summary: The study evaluated the safety and efficacy of raltitrexed in patients with metastatic colorectal cancer who had experienced serious adverse events with fluoropyrimidine-based therapy. Raltitrexed showed a median progression-free survival of 8.5 months and overall survival of 10.2 months, with no grade 4 adverse events or cardiotoxicity. The drug was well-tolerated and effective in this patient population.
CLINICAL COLORECTAL CANCER
(2021)
Article
Pharmacology & Pharmacy
Eric S. Christenson, Anthony Gizzi, Junru Cui, Matthew Egleston, Kyle J. Seamon, Michael DePasquale, Benjamin Orris, Ben H. Park, James T. Stivers
Summary: Selective inhibition of hUNG catalytic activity in cancer cell lines leads to increased sensitivity to FdU in colorectal cancer cells, indicating a potential therapeutic strategy. The mechanism of FdU differs from FU and hUNG inhibition does not correlate with p53 or TDG expression.
MOLECULAR PHARMACOLOGY
(2021)
Article
Oncology
Fanqi Meng, Chunlong Ai, Guoqiang Yan, Guangyi Wang
Summary: This study reveals the potential role of ZNF24 in reducing 5-FU resistance in CRC cells by suppressing the Wnt pathway and activating p53 signaling, offering a potential strategy for managing chemoresistance in CRC.
EXPERIMENTAL CELL RESEARCH
(2023)
Article
Oncology
Chul Min Yang, Moo-Koo Kang, Woong-Jae Jung, Jung-Sik Joo, Yong-Jin Kim, Yeeun Choi, Hyoung-Pyo Kim
Summary: p53, a critical tumor suppressor protein, influences drug sensitivity in a transcription-independent manner by regulating chromatin accessibility of genes associated with cell apoptosis. Treatment with 5-FU leads to global increases in chromatin accessibility, with chromatin organization in specific genomic regions being influenced by p53 expression status.
Article
Biophysics
Pengwei Hu, Miao Sun, Fengkun Lu, Sizhen Wang, Lei Hou, Yingjie Yu, Yunchang Zhang, Linhong Sun, Jianzhong Yao, Feng Yang, Chen Wang, Zhiqiang Ma
Summary: Combining PDT with HDACis enhances anti-tumor activity, but poor solubility and heterogeneous cellular uptake hinder the dual mode effect. Pyro@FPPS achieves controlled release of photosensitizers and HDACis, effectively inhibiting tumor proliferation and metastasis.
COLLOIDS AND SURFACES B-BIOINTERFACES
(2021)
Article
Biology
Marlies C. Ludikhuize, Sira Gevers, Nguyen T. B. Nguyen, Maaike Meerlo, S. Khadijeh Shafiei Roudbari, M. Can Gulersonmez, Edwin C. A. Stigter, Jarno Drost, Hans Clevers, Boudewijn M. T. Burgering, Maria J. Rodriguez Colman
Summary: In p53-deficient colorectal cancer organoids, 5-fluorouracil induces pyrimidine imbalance, which leads to DNA damage and cell death. Rewiring glucose metabolism through PDK inhibition by DCA enhances 5-FU toxicity in glycolytic p53-deficient organoids. This has important implications for improving chemotherapy strategies for colorectal cancer, and p53 emerges as a key factor in determining the response to 5-FU.
COMMUNICATIONS BIOLOGY
(2022)
Article
Pharmacology & Pharmacy
Xiao-Ling Liang, Lan Ouyang, Nan-Nan Yu, Zheng-Hua Sun, Zi-Kang Gui, Yu-Long Niu, Qing-Yu He, Jing Zhang, Yang Wang
Summary: This study identifies a potential anticancer therapy strategy by inducing cell death through shifting the scission position of mitochondria. The pan-HDAC inhibitor pracinostat is found to activate the CDK5-Drp1 signaling pathway, leading to mitochondrial fission and showing potential in CRC treatment.
JOURNAL OF PHARMACEUTICAL ANALYSIS
(2023)
Article
Biochemistry & Molecular Biology
Hsueh-Yun Lee, Di-Wei Tang, Chi-Yuan Liu, Er-Chieh Cho
Summary: This study focuses on the development of benzamide-based compounds as potential HDAC1/2 inhibitors for colorectal cancer treatment. Compound 9 is identified as a selective HDAC inhibitor with significant anticancer activity against colorectal cancer cells. The study also investigates the molecular regulatory mechanisms of compound 9, demonstrating its potential in apoptosis activation, cell cycle arrest induction, DNA damage facilitation, and cancer migration suppression in colorectal cancer cells.
CHEMICO-BIOLOGICAL INTERACTIONS
(2022)
Article
Oncology
Vincenza Granata, Roberta Fusco, Federica De Muzio, Carmen Cutolo, Sergio Venanzio Setola, Federica dell'Aversana, Alessandro Ottaiano, Antonio Avallone, Guglielmo Nasti, Francesca Grassi, Vincenzo Pilone, Vittorio Miele, Luca Brunese, Francesco Izzo, Antonella Petrillo
Summary: This study evaluated the usefulness of radiomics features obtained from contrast MRI studies as prognostic biomarkers in colorectal liver metastases patients. The results showed that these features had good performance in identifying tumor growth front, tumor budding, mucinous type, and recurrence. Furthermore, using linear regression models or neural network classifiers in a multivariate approach improved the accuracy, sensitivity, and specificity of the predictions.
Review
Oncology
Laura Grumetti, Rita Lombardi, Federica Iannelli, Biagio Pucci, Antonio Avallone, Elena Di Gennaro, Alfredo Budillon
Summary: This review focuses on the role of histone deacetylase inhibitors (HDACis) in the metabolism and resistance mechanisms of fluoropyrimidines. Studies have shown that HDACis can enhance the antitumor efficacy of fluoropyrimidines and overcome drug resistance. However, clinical studies have not fully confirmed these observations.
Article
Oncology
Maria Serena Roca, Tania Moccia, Federica Iannelli, Cristina Testa, Carlo Vitagliano, Michele Minopoli, Rosa Camerlingo, Giulia De Riso, Rossella De Cecio, Francesca Bruzzese, Mariarosaria Conte, Lucia Altucci, Elena Di Gennaro, Antonio Avallone, Alessandra Leone, Alfredo Budillon
Summary: This study investigated the potential of domatinostat in sensitizing PDAC to standard chemotherapeutic treatment. The results showed that domatinostat can enhance the sensitivity of PDAC to chemotherapy drugs by targeting cancer stem cells and inducing oxidative stress. Mechanistically, domatinostat reduces the expression and function of FOXM1, a transcription factor involved in stemness and DNA repair. The expression of FOXM1 is also correlated with the prognosis of chemotherapy-treated PDAC patients.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
(2022)
Article
Medicine, General & Internal
Vincenza Granata, Roberta Fusco, Federica De Muzio, Carmen Cutolo, Sergio Venanzio Setola, Federica Dell'Aversana, Andrea Belli, Carmela Romano, Alessandro Ottaiano, Guglielmo Nasti, Antonio Avallone, Vittorio Miele, Fabiana Tatangelo, Antonella Petrillo, Francesco Izzo
Summary: This study assessed the MRI features of mucinous liver metastases and found that mucinous metastases exhibited hypointense signal on T1-W, very high signal on T2-W with restricted diffusion, iso-hypointense signals in the ADC map, and peripheral progressive enhancement during the contrast study.
JOURNAL OF CLINICAL MEDICINE
(2022)
Article
Medicine, General & Internal
Daniela Rega, Vincenza Granata, Antonella Petrillo, Ugo Pace, Massimiliano Di Marzo, Roberta Fusco, Valeria D'Alessio, Guglielmo Nasti, Carmela Romano, Antonio Avallone, Vincenzo Ravo, Fabiana Tatangelo, Piera Maiolino, Raffaele Palaia, Francesco Izzo, Paolo Delrio
Summary: Electrochemotherapy (ECT) has shown effectiveness in treating deep solid tumors. Preliminary results in patients with locally advanced rectal cancer (LARC) treated with ECT demonstrated disease stabilization, pain reduction, and effective local control of recurrence.
JOURNAL OF CLINICAL MEDICINE
(2022)
Article
Medicine, General & Internal
Vincenza Granata, Roberta Fusco, Federica De Muzio, Carmen Cutolo, Mauro Mattace Raso, Michela Gabelloni, Antonio Avallone, Alessandro Ottaiano, Fabiana Tatangelo, Maria Chiara Brunese, Vittorio Miele, Francesco Izzo, Antonella Petrillo
Summary: Radiomics and Machine Learning Analysis based on EOB-MRI study allows to identify biomarkers for recognizing different Growth Patterns in CRLM.
Review
Biochemistry & Molecular Biology
Gerardo Rosati, Giuseppe Aprile, Alfredo Colombo, Stefano Cordio, Marianna Giampaglia, Alessandro Cappetta, Concetta Maria Porretto, Alfonso De Stefano, Domenico Bilancia, Antonio Avallone
Summary: Personalized treatments for metastatic colorectal cancer are necessary, and targeting specific biomarkers based on patients' genetic profiles is crucial. Various inhibitors have been developed for RAS and BRAF mutations, and specific antibodies are being tested for other mutations. This review assesses the reasons for expanding the molecular profile of patients and provides an overview of ongoing clinical trials.
Article
Medicine, Research & Experimental
Stefania Cocco, Alessandra Leone, Maria Serena Roca, Rita Lombardi, Michela Piezzo, Roberta Caputo, Chiara Ciardiello, Susan Costantini, Francesca Bruzzese, Maria Jose Sisalli, Alfredo Budillon, Michelino De Laurentiis
Summary: The study found that two PI3K/AKT inhibitors, ipatasertib and taselisib, induced autophagy signaling in different breast cancer models. This effect was particularly evident in PI3K/AKT resistant TNBC cells, where the inhibition of autophagy by CQ potentiated the therapeutic effect of PI3K/AKT inhibitors in vitro and in vivo TNBC models, synergizing with taxane-based chemotherapy.
JOURNAL OF TRANSLATIONAL MEDICINE
(2022)
Review
Oncology
Vincenza Granata, Roberta Fusco, Sergio Venanzio Setola, Roberta Galdiero, Nicola Maggialetti, Lucrezia Silvestro, Mario De Bellis, Elena Di Girolamo, Giulia Grazzini, Giuditta Chiti, Maria Chiara Brunese, Andrea Belli, Renato Patrone, Raffaele Palaia, Antonio Avallone, Antonella Petrillo, Francesco Izzo
Summary: Pancreatic cancer is one of the deadliest cancers, and late diagnosis is the main reason for its high mortality rate. Surgical resection is the only curative treatment, so early diagnosis is crucial for improving survival. Therefore, it is appropriate to stratify patients based on familial and genetic risk and develop screening protocols using minimally invasive diagnostic tools.
Article
Oncology
Susan Costantini, Elena Di Gennaro, Francesca Capone, Alfonso De Stefano, Guglielmo Nasti, Carlo Vitagliano, Sergio Venanzio Setola, Fabiana Tatangelo, Paolo Delrio, Francesco Izzo, Antonio Avallone, Alfredo Budillon
Summary: This study aimed to evaluate whether the integration of plasma metabolomics and lipidomics combined with the analysis of a large panel of plasma cytokines can be used to predict the risk of relapse and other patient outcomes after liver surgery. The results showed the potential of these combined biomarker approaches to predict outcomes in colorectal cancer patients.
FRONTIERS IN ONCOLOGY
(2023)
Article
Oncology
C. Cardone, A. De Stefano, G. Rosati, A. Cassata, L. Silvestro, M. Borrelli, E. Di Gennaro, C. Romano, A. Nappi, N. Zanaletti, F. Foschini, R. Casaretti, F. Tatangelo, S. Lastoria, M. Raddi, D. Bilancia, V. Granata, S. Setola, A. Petrillo, C. Vitagliano, P. Gargiulo, L. Arenare, A. Febbraro, E. Martinelli, F. Ciardiello, P. Delrio, A. Budillon, M. C. Piccirillo, A. Avallone
Summary: This study evaluated the activity of regorafenib in patients with RAS-mutant metastatic colorectal cancer. Regorafenib was found to be relatively well tolerated and effective in controlling disease progression, particularly in patients with favorable prognostic characteristics. Baseline metabolic assessment may be useful in selecting patients with a favorable outcome.
Article
Oncology
Davide Ciardiello, Stefania Napolitano, Vincenzo Famiglietti, Lucia Esposito, Vincenzo De Falco, Alessandra Di Liello, Antonio Avallone, Evaristo Maiello, Filippo Pietrantonio, Chiara Cremolini, Maria Giulia Zampino, Nicola Fazio, Teresa Troiani, Erika Martinelli, Fortunato Ciardiello, Giulia Martini
Summary: Rechallenge with EGFR inhibitors is a promising strategy in refractory RAS/BRAF wild-type metastatic colorectal cancer (mCRC) patients. The presence of plasma ctDNA RAS/BRAF mutations at pretreatment liquid biopsy analysis was not associated with the length of anti-EGFR drug-free interval. Liquid biopsy can be used to select suitable patients for EGFR inhibitor rechallenge.
Article
Oncology
Thierry Andre, Filippo Pietrantonio, Antonio Avallone, Mahmut Gumus, Lucjan Wyrwicz, Jong Gwang Kim, Suayib Yalcin, Mariusz Kwiatkowski, Sara Lonardi, Jakub Zolnierek, Amos Odeleye-Ajakaye, Pierre Leconte, David Fogelman, Tae Won Kim
Summary: Robust clinical activity has been observed with pembrolizumab in treating MSI-H/dMMR mCRC. However, there is still room for improvement in terms of response rate and progression-free survival. The KEYSTEP-008 trial aims to evaluate the efficacy and safety of pembrolizumab-based combination therapy compared with monotherapy in chemotherapy-refractory or previously untreated MSI-H/dMMR mCRC. Rating: 9/10
Article
Biochemistry & Molecular Biology
Susan Costantini, Gabriele Madonna, Elena Di Gennaro, Francesca Capone, Palmina Bagnara, Mariaelena Capone, Silvia Sale, Carmine Nicastro, Lidia Atripaldi, Giuseppe Fiorentino, Roberto Parrella, Vincenzo Montesarchio, Luigi Atripaldi, Paolo A. Ascierto, Alfredo Budillon
Summary: SARS-CoV-2 infection has a wide range of clinical manifestations, from asymptomatic to severe forms. The patients with the highest mortality rate exhibit a cytokine storm, similar to cancer-related inflammation. SARS-CoV-2 infection also leads to metabolic changes, which are closely linked to cancer metabolism. Understanding the correlation between perturbed metabolism and inflammatory responses is crucial.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Article
Health Care Sciences & Services
Marco Cascella, Emanuela Racca, Anna Nappi, Sergio Coluccia, Sabatino Maione, Livio Luongo, Francesca Guida, Antonio Avallone, Arturo Cuomo
Summary: This study developed a data-driven prediction model for identifying cancer patients at a higher risk for unplanned hospital readmissions (HRAs). The results showed that nutritional support and radiotherapy were directly related to HRAs, while breakthrough cancer pain (BTcP) did not significantly affect readmissions.